Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Evoke Pharma (EVOK) over the last 5 years, with Q3 2025 value amounting to $2.6 million.

  • Evoke Pharma's Shares Outstanding (Diluted Average) rose 8268.74% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 8268.74%. This contributed to the annual value of $1.9 million for FY2024, which is 58390.5% up from last year.
  • As of Q3 2025, Evoke Pharma's Shares Outstanding (Diluted Average) stood at $2.6 million, which was up 8268.74% from $2.6 million recorded in Q2 2025.
  • Evoke Pharma's Shares Outstanding (Diluted Average)'s 5-year high stood at $3.3 million during Q3 2022, with a 5-year trough of $278558.0 in Q2 2023.
  • Over the past 5 years, Evoke Pharma's median Shares Outstanding (Diluted Average) value was $2.6 million (recorded in 2025), while the average stood at $2.1 million.
  • Per our database at Business Quant, Evoke Pharma's Shares Outstanding (Diluted Average) tumbled by 9166.76% in 2023 and then skyrocketed by 58390.5% in 2024.
  • Evoke Pharma's Shares Outstanding (Diluted Average) (Quarter) stood at $2.7 million in 2021, then increased by 17.21% to $3.1 million in 2022, then crashed by 91.14% to $278558.0 in 2023, then skyrocketed by 583.9% to $1.9 million in 2024, then soared by 34.24% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $2.6 million for Q2 2025, and $2.5 million during Q1 2025.